Our study provides a new immunotherapy strategy for improving the cross-presentation ability of DC vaccines and targeting numerous tumors with high expression of MUC1 and PD-L1, such as invasive lung cancer, pancreas, prostate, epithelial ovarian cancer, platinum-resistant tumors, primary lung cancer and breast cancer. The gene discussed is MUC1; the disease is breast cancer.